1. Levinson DR. US Department of Health and Human Services, Office of Inspector General. Challenges to FDA’s ability to monitor and inspect foreign clinical trials, 2001. OEI-01-08-00510. Accessed 19th November 2014 from http://oig.hhs.gov/oei/reports/oei-01-08-00510.pdf
2. European Medicines Agency. Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted outside of the EU/EEA and submitted in marketing authorisation applications to the EU Regulatory Authorities, 2012. EMA/121340/2011. Accessed 19th November 2014 from http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125437.pdf
3. Burrows JN, Elliott RL, Kaneko T, Mowbray CE, Waterson D. The role of modern drug discovery in the fight against neglected and tropical diseases. Med Chem Commun. 2014;5:688–700.
4. G-Finder. Neglected diseases research and development: the public divide. Policy Cures 2013, Sydney, Australia. Accessed 19th November 2014 from http://www.policycures.org/downloads/GF_report13_all_web.pdf
5. Kilama WL, Chilengi R, Wanga CL. Towards an African-Driven Malaria Vaccine Development Program: History and Activities of the African Malaria Network Trust (AMANET). Am J Trop Med Hyg. 2007;77 Suppl 6:282–8.